We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Revised Guidance on Developing Drugs for Complicated UTIs
FDA Issues Revised Guidance on Developing Drugs for Complicated UTIs
The resolution of all original symptoms should be the primary efficacy endpoint in trials for complicated urinary tract infection drugs, according to a new FDA guidance.